Cardiometabolic & kidney

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis

Eur Heart JPublished Prespecified subgroup analysis of the FIND-CKD randomised trial

Primary result · Total eGFR slope, hypertensive nephropathy subgroupResult — go to the resultDifference 0.65 mL/min/1.73 m²/year 95% CI 0.02–1.29

Authors' conclusion

Finerenone slowed eGFR decline and reduced kidney-cardiovascular outcome risk in participants with hypertensive nephropathy

Study context

Population
Adults with non-diabetic CKD (estimated glomerular filtration rate (eGFR) 25-<90 mL/min/1.73 m², urinary albumin-to-creatinine ratio (UACR) 200–3500 mg/g) and investigator-reported hypertensive nephropathyof 1584 randomised
Participants
459 adults
Comparison
Finerenone vs placebo
Primary endpoint
Total eGFR slope
Follow-up
Baseline to Month 32
Methodological detailsplacebo-controlled, 1:1 randomisation
  • Placebo-controlled
  • 1:1 randomisation

Primary result

As reported in the abstract

Total eGFR slope, hypertensive nephropathy subgroup

Difference

0.65 mL/min/1.73 m²/year

95% CI 0.02–1.29

P = 0.044

Finerenone vs Placebo
difference 0.65 mL/min/1.73 m²/year (95% CI 0.02–1.29); P = 0.044

Further findings

OutcomeHR (95% CI)P value
Kidney-CV composite (sustained ≥57% eGFR decline, kidney failure, HF hospitalisation or CV death), hypertensive nephropathy subgroup0.61 (0.38–0.99)P = 0.045
OutcomeDifference (mmHg)P value
SBP and UACR · Month 6 · SBP−3.5
Systolic blood pressure (SBP) and UACR — UACR reduction with finerenone vs placebo
33%
  • Kidney-CV composite (sustained ≥57% eGFR decline, kidney failure, HF hospitalisation or CV death), hypertensive nephropathy subgroup: consistent irrespective of baseline SBP (interaction P 0.91)

Safety

Hyperkalaemia

Hyperkalaemia-related discontinuation

Original publication

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis. Eur Heart J. Published 30 August 2026. doi:10.1093/eurheartj/ehag729

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.